#substrate reduction therapy

A Beacon of Hope: Sanofi's Venglustat Receives US FDA Breakthrough Therapy Designation for Type 3 Gaucher Disease

In a momentous development for the rare disease community, Sanofi's investigational therapy, venglustat, has been granted Breakthrough Therapy Designation by the US FDA for Type 3 Gaucher Disease. This designation recognizes the urgent need for effective treatments for the severe neurological manifestations of this debilitating condition and promises to accelerate the path to potential approval, offering renewed hope to patients and their families.